Nivolumab-induced Lambert-Eaton myasthenic syndrome: an immune-related adverse event in nonsmall cell lung cancer

3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials

(2021) Na Zhang et al.   BMC Neurology

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

(2019) Shi Zhou et al.   Therapeutics and Clinical Risk Management

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

(2019) Yucai Wang et al.   JAMA Oncology

Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis

(2019) Puyuan Xing et al.   Journal for ImmunoTherapy of Cancer

Lambert-Eaton Myasthenic Syndrome

(2018) Vita G. Kesner et al.   NEUROLOGIC CLINICS

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma

(2017) Yu-Hsiu Chen et al.   MEDICINE

Automated Classification of Lung Cancer Types from Cytological Images Using Deep Convolutional Neural Networks

(2017) Atsushi Teramoto et al.   Biomed Research International

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY